Australian Crohn's antibiotic study opens new horizons.
Gitlin
Laura
L
Biesecker
James
J
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage; D002991:Clofazimine / Q000008:administration & dosage; D003424:Crohn Disease / Q000188:drug therapy* / Q000821:virology*; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000008:administration & dosage; D006801:Humans; D000069285:Infliximab; D016927:Mycobacterium avium subsp. paratuberculosis / Q000472:pathogenicity*; D010283:Paratuberculosis / Q000150:complications* / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D015203:Reproducibility of Results; D017828:Rifabutin / Q000008:administration & dosage; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D017828:Rifabutin; D000069285:Infliximab; D002991:Clofazimine; D017291:Clarithromycin